Send me real-time posts from this site at my email

Colfax (CFX) Q4 Earnings Top Estimates, 2021 View Impressive

Colfax Corporation CFX reported better-than-expected results for fourth-quarter 2020, with earnings surpassing estimates by 4.1%. This was the company’s 21st consecutive quarter of impressive bottom-line results. However, the quarter’s sales lagged the Zacks Consensus Estimate by 0.3%.

The machinery company’s adjusted earnings in the reported quarter were 51 cents per share, surpassing the consensus estimate of 49 cents. However, the bottom line declined 16.4% from the year-ago figure of 61 cents on weak sales generation and a fall in margin.

For 2020, the company’s adjusted earnings were $1.40 per share, surpassing the Zacks Consensus Estimate of $1.38. However, the results were 30.3% below the year-ago figure of $2.01.

Revenue Details

In the quarter under review, Colfax’s net sales were $828.1 million, reflecting a year-over-year decline of 6.8%. The results suffered from a 7.4% decline in the existing businesses (due to the pandemic’s impact on demand) and a 0.2% impact of forex woes. However, acquisitions had a positive impact of 0.8% in the quarter.

Also, the company’s revenues lagged the Zacks Consensus Estimate of $830.2 million.

Notably, its net sales increased 3% from the previous quarter’s figure.

The company currently reports under two business segments — Fabrication Technology and Medical Technology. The segmental information is briefly discussed below:

Revenues from Fabrication Technology totaled $518.6 million, declining 6.5% year over year. The results suffered from a 5.2% decline in existing businesses and a 1.3% adverse impact of forex woes.

Revenues from Medical Technology totaled $309.5 million, reflecting a year-over-year decline of 7.3%. The results suffered from an 11% fall in existing businesses, partially offset by a 7.3% gain from acquired assets and a 1.6% positive impact of movements in foreign currencies.

For 2020, the company’s net sales were $3.1 billion, decreasing 12.2% from the previous year. Also, the sales lagged the Zacks Consensus Estimate of $3.07 billion.

Margin Profile

In the quarter under review, Colfax’s cost of sales declined 3.9% year over year to $473.4 million. Selling, general and administrative expenses decreased 1.6% year over year to $281.4 million. It represented 34% of revenues.

Adjusted earnings before interest, tax and amortization (EBITA) in the quarter under review declined 15.7% year over year to $112.8 million. Also, the adjusted EBITA margin decreased 1.5 percentage points year over year to 13.6%. Interest expenses in the quarter declined 21.6% year over year to $25.6 million. Adjusted tax rate in the quarter was 18%.

Balance Sheet and Cash Flow

Exiting the fourth quarter, Colfax had cash and cash equivalents of $97.1 million, up 46.2% from the previous quarter’s figure of $66.4 million. Its long-term debt balance was up 0.6% sequentially to $2,204.2 million.

Notably, the company repaid borrowings of $939 million under its revolving credit facilities and others in 2020. Further, it raised $860.7 million in cash through the same means.

In 2020, Colfax generated net cash of $301.9 million from operating activities as compared with $130.9 million in the previous year. Capital used for purchasing property, plant and equipment was $114.8 million, reflecting a year-over-year decline of 8.5%.


Colfax anticipates a healthy increase in sales and earnings in 2021. It also expects the cash flow position to be impressive in the year. It anticipates recovering demand to aid the top-line performance.

Revenues are expected to increase 15-18% year over year in 2021. On a segmental basis, sales for Medical Technology are expected to be up 21-24% (or 14-16% on an organic basis), while the same for Fabrication Technology is expected to increase 11-14% (or 9-12% organically).

Adjusted earnings per share are expected to be $2.00-$2.15 per share, up from $1.40 in 2020. Free cash flow is will be at least $250 million for the year.

For the first quarter of 2021, adjusted earnings per share are predicted to be 35-40 cents per share.

Colfax Corporation Price, Consensus and EPS Surprise


Colfax Corporation price-consensus-eps-surprise-chart | Colfax Corporation Quote

Zacks Rank & Stock to Consider

With a market capitalization of $4.7 billion, the company currently carries a Zacks Rank #4 (Sell).

Three better-ranked stocks in the industry are Applied Industrial Technologies, Inc. AIT, Graco Inc. GGG and EnPro Industries, Inc. NPO. These companies currently carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

In the past 30 days, earnings estimates for Applied Industrial and Graco improved for the current year, while the same has been unchanged for EnPro. Further, earnings surprise for the last reported quarter was 28.95% for Applied Industrial, 19.61% for Graco and 109.38% for EnPro.

These Stocks Are Poised to Soar Past the Pandemic

The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.

Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.

See the 5 high-tech stocks now>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Applied Industrial Technologies, Inc. (AIT): Free Stock Analysis Report
Graco Inc. (GGG): Free Stock Analysis Report
Colfax Corporation (CFX): Get Free Report
EnPro Industries (NPO): Free Stock Analysis Report
To read this article on click here.

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue